cbdMD (YCBD) Amortization of Deferred Charges (2016 - 2025)
cbdMD (YCBD) reported Amortization of Deferred Charges of $171188.0 for Q4 2025, up 316.2% on a YoY basis from $41131.0 in Q4 2024, and little changed sequentially from $170472.0 in Q3 2025.
cbdMD (YCBD) Amortization of Deferred Charges (2016 - 2025) Analysis & Trends
cbdMD (YCBD) has 7 years of Amortization of Deferred Charges data on file, last reported at $171188.0 in Q4 2025.
- For the quarter ending Q4 2025, Amortization of Deferred Charges rose 316.2% year-over-year to $171188.0; the trailing twelve-month figure through Dec 2025 stood at $799838.0 (up 89.85% YoY), and the FY2025 full-year result was $669781.0, changed 0.13% from the prior year.
- Amortization of Deferred Charges held at $171188.0 in Q4 2025, from $170472.0 in the prior quarter.
- In the past five years, Amortization of Deferred Charges ranged from a high of $318017.0 in Q4 2021 to a low of -$211778.0 in Q3 2024.
- A 5-year average of $222099.1 and a median of $276636.0 in 2022 frame the typical range for Amortization of Deferred Charges.
- Across the five-year window, Amortization of Deferred Charges slumped 173.82% in 2024 and surged 316.2% in 2025, its largest moves.
- Tracing YCBD's Amortization of Deferred Charges over 5 years: stood at $318017.0 in 2021, then fell by 13.01% to $276636.0 in 2022, then rose by 5.0% to $290459.0 in 2023, then slumped by 85.84% to $41131.0 in 2024, then surged by 316.2% to $171188.0 in 2025.
- Business Quant data shows YCBD's Amortization of Deferred Charges at $171188.0 in Q4 2025, $170472.0 in Q3 2025, and $168340.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | cbdMD | 438,678.80 | -2.95 Mn | 3.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 171,188.00 |
| Dec 31, 2025 | 171,188.00 |
| Sep 30, 2025 | 170,472.00 |
| Sep 30, 2025 | 170,472.00 |
| Jun 30, 2025 | 168,340.00 |
| Jun 30, 2025 | 168,340.00 |
| Mar 31, 2025 | 289,838.00 |
| Mar 31, 2025 | 289,838.00 |
| Dec 31, 2024 | 41,131.00 |
| Dec 31, 2024 | 41,131.00 |
| Sep 30, 2024 | -211,778.00 |
| Sep 30, 2024 | -211,778.00 |
| Jun 30, 2024 | 297,825.00 |
| Jun 30, 2024 | 297,825.00 |
| Mar 31, 2024 | 294,115.00 |
| Mar 31, 2024 | 294,115.00 |
| Dec 31, 2023 | 290,459.00 |
| Dec 31, 2023 | 290,459.00 |
| Sep 30, 2023 | 286,897.00 |
| Sep 30, 2023 | 286,897.00 |